ReviewJournal of inflammation research2022
Topical Anti-Inflammatory Agents for Non-Infectious Uveitis: Current Treatment and Perspectives.
Review in Journal of inflammation research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- A systematic review of ultrasound-mediated drug delivery to the eye and critical insights to facilitate a timely path to the clinic.Theranostics · 2023Pooled it
- Self-assembled non-steroidal anti-inflammatory drug-peptide hydrogel to effectively mitigate ocular inflammation.Drug delivery · 2026Article
- Filomicelle-Embedded Composite Hydrogels for Localized Gelation Within the Anterior Chamber of the Eye.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Muscone Attenuates Uveitis Through the PI3K/AKT Signaling Pathway.Investigative ophthalmology & visual science · 2025Article
- Safe Use of Corticosteroids in Non-Infectious Uveitis.Journal of inflammation research · 2025Review
- Beyond the joints: mechanistic insights and multidisciplinary strategies for spondyloarthritis-associated uveitis.Frontiers in immunology · 2025Review
- Design and Evaluation of a Dual-Sensitive In Situ Gel for the Controlled Release of Pranoprofen.AAPS PharmSciTech · 2024Article
- Review
- Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond.Frontiers in ophthalmology · 2024Review
- Local Myeloid-Derived Suppressor Cells Impair Progression of Experimental Autoimmune Uveitis by Alleviating Oxidative Stress and Inflammation.Investigative ophthalmology & visual science · 2023Article
- Impact of the Coronavirus Disease 2019 Pandemic on Initiation Therapy for Noninfectious Uveitis.Ophthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-infectious uveitis represents a heterogenous group of immune-mediated ocular diseases, which can be associated with underlying systemic disease. While the initial choice of treatment of non-infectious uveitis depends on a number of factors such as anatomical location and degree of inflammation, topical therapies often remain the initial choice of non-invasive therapy. In this narrative review, we aim to describe the literature on non-infectious uveitis, with specific focus on the current perspective on topical anti-inflammatory therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.